Chlorthalidone blood pressure drug recalled twice in four months over dissolution failures

Overview

Updated 1 hour ago

An Indian drugmaker has recalled a common blood pressure medicine twice since June. Inventia Healthcare pulled more than 25,000 bottles of its 25 mg chlorthalidone tablets after lab tests showed the pills dissolve too slowly for proper absorption.

The problem is potency, not contamination. Slower dissolution means less drug reaches the bloodstream, so blood pressure can drift upward without symptoms. The Food and Drug Administration rated both recalls Class II, meaning temporary or reversible harm is possible and serious harm is unlikely.

Why it matters

Patients with recalled chlorthalidone may absorb less active drug than prescribed, and stopping the medicine suddenly can raise blood pressure.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

25,000+

Bottles recalled in two actions

11,460 in June plus 13,567 in September, both from Inventia Healthcare

13,567

Bottles in September recall (batch RISA24002)

100-count bottles, NDC 64980-599-01, expiration April 2027

78%

Drug released in June stability test

Below the 80% minimum for dissolution, meaning slower absorption

Class II

FDA risk classification for both recalls

Temporary or reversible harm possible; serious harm remote

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Organizations Involved

Inventia Healthcare Limited

Pharmaceutical manufacturer

Manufacturer of recalled chlorthalidone tablets

India-based pharmaceutical maker whose chlorthalidone 25 mg tablets are distributed in the United States.

U.S. Food and Drug Administration

Federal regulatory agency

Classified both recalls as Class II

The U.S. agency that regulates drug safety and classifies product recalls by health risk.

Rising Pharma Holdings

Pharmaceutical distributor

U.S. distributor of the recalled chlorthalidone

The U.S. distributor that holds the NDC code 64980-599-01 on the recalled bottles.

Timeline

June 2026 September 2026

5 events Latest: 2 days ago

Tap a bar to jump to that date

September 2026
Combined recall scale reported nationally
Latest Reporting

Wikipedia's current events portal notes that the two recalls together cover more than 25,000 bottles of chlorthalidone.
2 days ago
FDA assigns Class II to September recall
Regulatory action

The FDA lists the September recall as Class II under recall number D-0852-2026 in its Enforcement Report.
September 17th, 2026
Second recall of chlorthalidone
Recall

Inventia recalls 13,567 bottles (batch RISA24002, 100-count, expiration April 2027) for the same dissolution defect.
September 3rd, 2026
June 2026
FDA classifies June recall as Class II
Regulatory action

A stability test shows tablets released 78% of the drug, below the 80% dissolution minimum.
June 22nd, 2026
First recall of chlorthalidone
Recall

Inventia Healthcare recalls 11,460 bottles of 25 mg chlorthalidone (batches RISA24001 and RISB24002) after dissolution test failure.
June 5th, 2026

Scenarios

Recalls conclude; patients switch to other manufacturers

Possible Resolves by Q1 2027

Discussed by: FDA Enforcement Report monitoring; pharmacy recall watchers

If no new batches fail stability testing, the two recalls cover the affected lots and the story closes. Pharmacists substitute chlorthalidone from other manufacturers, and patients who check their bottles against NDC 64980-599-01 and lot RISA24002 confirm whether their pills are affected. The repeat failure makes this outcome depend on no third batch surfacing.

Third recall of another batch from the same plant

Likely Resolves by Q1 2027

Discussed by: Analysis of recurring failures across RISA24001, RISB24002, and RISA24002

Dissolution failures in three separate batches point to a process problem at Inventia's Ambernath plant rather than a one-off event. A stability test on another batch could catch the same defect and trigger a further recall, widening the supply disruption for patients who depend on this generic.

FDA inspects Inventia's Ambernath facility

Possible Resolves by Q2 2027

Discussed by: FDA inspection records; regulatory observers

Repeat Class II recalls for the same defect may prompt an FDA inspection of Inventia's manufacturing plant in Ambernath, India. An inspection could produce a Form 483 listing observed violations or an import alert restricting future shipments of the drug into the United States.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

July 2018 - 2019

Valsartan recalls (2018-2019)

In July 2018, the FDA expanded a recall of valsartan, a widely used blood pressure drug, after tests found NDMA, a probable carcinogen, in tablets made by Zhejiang Huahai Pharmaceuticals in China and other overseas plants. The recall grew to cover losartan and irbesartan from multiple manufacturers.

Then

Tens of millions of patients needed replacement drugs, and the FDA issued import alerts against several foreign active-ingredient suppliers.

Now

The episode pushed the FDA to tighten oversight of foreign suppliers and set stricter limits on nitrosamine impurities in common medicines.

Why this matters now

Like chlorthalidone, valsartan is a chronic blood pressure medicine whose U.S. supply depends on overseas manufacturers. A quality failure at one foreign plant forced mass substitutions for American patients.

2020

Metformin recalls (2020)

In 2020, the FDA recalled extended-release metformin, the most prescribed type 2 diabetes drug, after finding NDMA above acceptable limits in tablets from several manufacturers, including Indian firms such as Marksans and Aurobindo.

Then

Millions of tablets were pulled from U.S. pharmacy shelves, and patients switched to alternative forms or brands of the drug.

Now

Repeated recalls exposed the FDA's reliance on manufacturers' own testing data for imported generics, and led to nitrosamine limit guidance for drugmakers.

Why this matters now

Shows how a chronic-disease generic made in India can fail quality tests and create nationwide supply disruption for patients who take it every day.